De Novo Truncating Mutations in AHDC1 in Individuals with Syndromic Expressive Language Delay, Hypotonia, and Sleep Apnea

Fan Xia,1 Matthew N. Bainbridge,2 Tiong Yang Tan,3,4 Michael F. Wangler,1,5 Angela E. Scheuerle,6 Elaine H. Zackai,7 Margaret H. Harr,7 V. Reid Sutton,1,5 Roopa L. Nalam,8 Wenmiao Zhu,1 Margot Nash,3 Monique M. Ryan,3 Joy Yapilito-Lee,3 Jill V. Hunter,5 Matthew A. Deardorff,7 Samantha J. Penney,1 Arthur L. Beaudet,1 Sharon E. Plon,1,5 Eric A. Boerwinkle,2,9 James R. Lupski,1,5 Christine M. Eng,1 Donna M. Muzny,2 Yaping Yang,1 and Richard A. Gibbs1,2,*

Clinical whole-exome sequencing (WES) for identification of mutations leading to Mendelian disease has been offered to the medical community since 2011. Clinically undiagnosed neurological disorders are the most frequent basis for test referral, and currently, approximately 25% of such cases are diagnosed at the molecular level. To date, there are approximately 4,000 “known” disease-associated loci, and many are associated with striking dysmorphic features, making genotype-phenotype correlations relatively straightforward. A significant fraction of cases, however, lack characteristic dysmorphism or clinical pathognomonic traits and are dependent upon molecular tests for definitive diagnoses. Further, many molecular diagnoses are guided by recent gene-disease association discoveries. Hence, there is a critical interplay between clinical testing and research leading to gene-disease association discovery. Here, we describe four probands, all of whom presented with hypotonia, intellectual disability, global developmental delay, and mildly dysmorphic facial features. Three of the four also had sleep apnea. Each was a simplex case without a remarkable family history. Using WES, we identified AHDC1 de novo truncating mutations that most likely cause this genetic syndrome.

De novo pathogenic mutations are a major cause of sporadic human genetic disease.1,2 Whole-exome sequencing (WES)1 using next-generation-sequencing methods has proven to be a powerful tool for molecular diagnosis of mutations in genes known to underlie Mendelian disease,3 as well as for the discovery of novel disease-associated loci.1 Despite the rapid development of these new molecular tools, the majority of individuals who are suspected to have a genetic disease remain undiagnosed. In part, this reflects the incomplete status of the catalog of characterized Mendelian-disease-associated genes; this catalog currently includes about 4,000 entries and represents less than one-quarter of the annotated genes (~21,000) in the human genome.

We applied WES to identify de novo genetic changes in a parent-offspring trio in which the proband exhibited developmental delay, hypotonia, mild dysmorphic features, sleep apnea, and other symptoms (Figure 1; Table S1, available online). A truncating de novo mutant allele was found in AT-hook, DNA-binding motif, containing 1 (AHDC1 [RefSeq accession number NM_001029882.2]). We subsequently identified an additional three independent simplex cases with similar phenotypes and de novo truncating events in the same gene. This pattern of de novo variation in AHDC1 is highly unlikely to have occurred by chance and most likely represents the underlying cause of the symptoms in these individuals.

Subject 1 was an 18-month-old female (born to unrelated parents) who presented with hypotonia, delayed motor milestones, dysmorphic features, hepatomegaly, and laryngomalacia (Figure 2). Both the healthy parents and the proband were analyzed by WES.1 Informed consent was obtained, and all procedures were followed in accordance with the ethical standards prescribed and approved by the Baylor College of Medicine Institutional Review Board. The DNA from each of the three samples was sequenced at an average depth of coverage of greater than 120-fold, and greater than 95% of the targeted bases were covered at 20-fold or higher. The results identified de novo events, including single-nucleotide variants (SNVs) or small indel mutations in the proband, in five genes: c.415G>A (p.Glu139Lys) in CALY (MIM 604647; RefSeq NM_015722.3), c.1429G>A (p.Gly477Arg) in PTPRB (MIM 176882; RefSeq NM_001109754.2), c.1076C>G (p.Cys791Trpfs*57) in AHDC1 (RefSeq accession number NM_001029882.2); all sequence coordinates are based on human reference genome hg19 (UCSC Genome Browser). A comparison of the minor allele frequencies between these variants and similar mutations in the NHLBI Exome Sequencing Project Exome Variant Server (EVS) and a local variant database (see below) eliminated three missense mutations and one putative

1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; 2Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; 3Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, VIC 3052, Australia; 4Department of Pediatrics, University of Melbourne, Parkville VIC 3052, Australia; 5Texas Children’s Hospital, Houston, TX 77030, USA; 6Tesserae Genetics, Dallas, TX 75230, USA; 7The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; 8Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; 9Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
*Correspondence: agibbs@bcm.edu
http://dx.doi.org/10.1016/j.ajhg.2014.04.006. ©2014 by The American Society of Human Genetics. All rights reserved.
frameshift mutation as likely disease-causing candidates because of their occurrence in individuals without suspected developmental disorders. The remaining variant, the de novo deletion mutation in \textit{AHDC1} (c.2373_2374delTG), results in a frameshift of the \textit{AHDC1} open reading frame, beginning at codon 791, and by conceptual translation is predicted to cause a premature termination codon (p.Cys791Trpfs*57). Predicted truncating mutations in \textit{AHDC1} are absent from the 1000 Genomes database (healthy individuals), the EVS (about 6,500 individuals), and a database of exome data from the Atherosclerosis Risk in Communities study (approximately 8,000 community-based individuals). The absence of truncating mutations in \textit{AHDC1} in these databases suggests that such gene perturbations are not consistent with general good health, and therefore the observed \textit{AHDC1} mutation was considered likely to be pathogenic.

We next screened 2,000 entries of clinical WES data at the Whole Genome Laboratory at Baylor College of Medicine to identify possible additional \textit{AHDC1} mutations. Those data consist primarily of individuals who had a sample submitted by their physician for clinical WES, as previously described.\(^1\) The clinical WES test focuses on exome sequencing of the proband, and complete parental WES data are not routinely generated. Among 2,000 previously tested individuals, of whom 1,700 had developmental delay and/or intellectual disabilities, three were found to harbor frameshift alleles in \textit{AHDC1} (c.2898delC [p.Tyr967Thrfs*175] at chr1: 27,875,729, c.2373_2374delTG [p.Cys791Trpfs*57] at chr1: 27,876,253–27,876,254, and c.2547delC [p.Ser850Profs*82] at chr1: 27,876,080; Figures 1 and 3). The

---

**Figure 1. Pedigrees and Mutations of Four Affected Families**

---

**Table 1. Major Clinical Features of Four Probands**

<table>
<thead>
<tr>
<th>Subject</th>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
<th>(4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>female</td>
<td>female</td>
<td>male</td>
<td>male</td>
</tr>
<tr>
<td>Age</td>
<td>18 months</td>
<td>4 years</td>
<td>8 years</td>
<td>11 years</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>European descent</td>
<td>South Asian</td>
<td>European descent</td>
<td>European descent</td>
</tr>
<tr>
<td>Intellectual disability</td>
<td>NA</td>
<td>moderate</td>
<td>mild</td>
<td>moderate to severe</td>
</tr>
<tr>
<td>Speech delay</td>
<td>no words at 18 months of age</td>
<td>two words at 4 years of age</td>
<td>first words after 1 year of age, persistent speech therapy</td>
<td>no words, noncommunicating autism</td>
</tr>
<tr>
<td>Motor delay</td>
<td>no sitting at 18 months of age</td>
<td>sitting at 19 months of age, walking at 24 months of age</td>
<td>sitting at 9 months of age, walking at 18 months of age</td>
<td>sitting at 15 months of age, no independent ambulation</td>
</tr>
<tr>
<td>Hypotonia and failure to thrive</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Dysmorphic facial features</td>
<td>low-set ears, esotropia, upslanting palpebral fissures, micrognathia, flat nasal bridge</td>
<td>protuberant ears, upslanting palpebral fissures, flat nasal bridge</td>
<td>protuberant low-set ears, small earlobes, hypertelorism, downslanting palpebral fissures, mild ptosis, micrognathia</td>
<td>upturned earlobes, hypertelorism, esotropia, flat nasal bridge</td>
</tr>
<tr>
<td>Anatomic upper-airway obstruction</td>
<td>laryngomalacia, obstructive sleep apnea</td>
<td>obstructive sleep apnea</td>
<td>laryngomalacia, obstructive sleep apnea</td>
<td>suspected tracheomalacia in infancy, history of snoring</td>
</tr>
<tr>
<td>Family history</td>
<td>negative, one healthy sibling</td>
<td>negative</td>
<td>negative, one healthy sibling</td>
<td>negative, two healthy siblings</td>
</tr>
<tr>
<td>Previous testing</td>
<td>MD, SMA, PWS, CMA, metabolic work-up</td>
<td>FX, CMA (18 Mb AOH on chromosome 5), metabolic work-up</td>
<td>CMA, FX, metabolic work-up</td>
<td>SMA, PWS, CMA, metabolic work-up</td>
</tr>
</tbody>
</table>

---

See Table S1 for additional details of clinical presentations. Abbreviations are as follows: AOH, absence of heterozygosity; CMA, chromosome microarray; FX, fragile X chromosome; MD, myotonic dystrophy; NA, not available; PWS, Prader-Willi syndrome; and SMA, spinal muscular atrophy.
mutations in the three individuals were further demonstrated by PCR and Sanger DNA sequencing to be absent in maternal and paternal DNA and were therefore interpreted as de novo events. Interestingly, subjects 1 and 3 had the same de novo mutation (c.2373_2374delTG [p.Cys791Trpfs*57]). Except for the \textit{AHDC1} mutations, we did not find other molecular events that could potentially explain the conditions in these probands. Therefore, the de novo mutations observed here in \textit{AHDC1} are the most likely causes of the disease.

Clinical review of the four probands with \textit{AHCD1} truncating mutations revealed that all had a history of congenital hypotonia and failure to thrive (Table 1; Table S1). The developmental histories were all remarkable for delayed speech, especially expressive language. All had mildly dysmorphic facial features that could be seen at a young age, and those of subject 4 persisted at an older age. Three probands also had a history of obstructive sleep apnea, potentially because of upper-airway structural abnormalities. All probands had prior brain MRI demonstrating hypoplasia of the corpus callosum. Simplification of the gyral pattern and delayed myelination were also observed. A retrocerebellar cyst was present in two of the four subjects (Figure S1).

The independent occurrence of four de novo mutational events at this locus in individuals with similar phenotypes is highly unlikely (discussed in Bainbridge et al.) and can be asserted as extremely strong evidence that these mutations in \textit{ACHD1} cause this simplex disorder. To the best of our knowledge, the overall clinical presentations of these probands do not precisely match any previously known disease and, together with the statistical and molecular data, suggest a genetic syndrome defined by the mutations in \textit{AHDC1}.

In subject 4, we also identified a de novo missense change, c.2006A>C (p.Asp669Ala), in \textit{ANKRD11} (MIM 611192; RefSeq NM_013275.5). Haploinsufficiency of \textit{ANKRD11} has been associated with KBG syndrome (MIM 110107).

Figure 2. Facial Features of Probands
(A) Subject 1 (17 months old) with a round face, full cheeks, horizontal eyebrows, a depressed nasal bridge, anteverted nares, hypoplastic alae nasi, tented upper-lip vermillion, and microstomia.
(B) Subject 2 (4 years old) with thin eyebrows, a depressed nasal bridge, a bulbous nasal tip, and protuberant ears.
(C) Subject 3 (8 years old) with horizontal eyebrows, low-set ears, simple earlobes, and micrognathia.
(D) Subject 4 (21 months old) with a round face, full cheeks, horizontal eyebrows, a depressed nasal bridge, anteverted nares, tented upper-lip vermillion, and microstomia.
(E and F) Front (E) and side (F) views of subject 4 (9 years old) with a round face, full cheeks, horizontal eyebrows, an acute nasal angle, and fleshy pinna.
148050), characterized by macrodontia, variable facial dysmorphic features, mild skeletal anomalies, seizures in some individuals, and mild to moderate intellectual disability. However, the proband reported here did not have macrodontia, skeletal defects, or other features of KGB phenotypes and therefore did not meet the KBG diagnostic criteria proposed by Skjei et al.\(^7\) Additionally, the well-characterized pathogenic mutations in \textit{ANKRD11} are truncating.\(^8\) Thus, the significance of \textit{ANKRD11} missense variant c.2006A\(\rightarrow\)C (p.Asp669Ala) is unclear.

\textit{AHDC1} is located on the short arm of chromosome 1 within the cytogenetic band 1p36.11, but it is more proximal than the regions identified from partial or complete monosomy of 1p36,\(^9\) other small interstitial deletions,\(^10,11\) and the nearby \textit{ARID1A}, mutations in which cause autosomal-dominant Coffin-Siris syndrome\(^12\) (MIM 135900). In the RefSeq and CCDS databases, the structural organization of \textit{AHDC1} includes five untranslated exons upstream of a single 4,929 bp coding exon followed by a single downstream exon. This intronless coding structure is a common feature for newly evolved genes created by RNA-based retroposition.\(^13\) Indeed, orthologs of \textit{AHDC1} can only be found in vertebrate animals. Gaining intron structures during evolution is correlated with higher expression levels.\(^14\) The expression level and patterns of \textit{AHDC1} are more similar to those of the multi-intron \textit{ARID1A} than to those of the intronless \textit{FOXG1} (MIM 164874), two other genes associated with severe developmental disorders in humans (Figure S2). Therefore, it can be postulated that the introns of the UTRs of \textit{AHDC1} affect and/or enhance the expression levels in various human tissues. On the nucleotide level, the single coding exon of \textit{AHDC1} is well conserved among vertebrates (Figure 3). The 3’ untranslated exon also shows conservation levels similar to those of the coding region, suggesting a potential functional significance of this exon.

Human \textit{AHDC1} encodes a protein of 1,603 amino acids. By aligning human \textit{AHDC1} against the protein sequences of \textit{AHDC1} orthologs in mouse, zebrafish, and western clawed frog, we found that the conserved amino acids are clustered into two regions (Figure 3C; Figure S3), suggesting two functional units. \textit{AHDC1} has two AT-hook DNA-binding motifs located at codons 396–408 and 544–556, contained in conserved region 1. AT-hook domains are DNA-binding motifs that act to fasten proteins to AT-rich sequences in DNA.\(^15\) Although conserved, region 2
contains no known functional domains. In vitro protein-interaction assays have shown that AHDC1 interacts with a number of other nuclear proteins. Therefore, conserved regions 1 and 2 of AHDC1 might interact with the DNA elements or protein partners. Interestingly, all of the de novo mutations found in these four probands might truncate conserved region 2 but preserve region 1. Given that each mutation identified here occurs in a single coding exon, the modified mRNA might escape nonsense-mediated decay, suggesting that the autosomal-dominant mode of inheritance of these mutations is possibly due to the formation of dominant-negative proteins rather than haploinsufficiency.

Future research to better delineate the functional domains of AHDC1 is now enhanced by the phenotypic association with the truncating mutations reported here. Also, the phenotypes of the four probands are clearly similar in retrospect. However, speech delay and obstructive sleep apnea are sufficiently common conditions that it is unlikely that this syndrome would have been identified if the de novo mutations had not been uncovered first.

Supplemental Data
Supplemental Data include three figures and one table and can be found with this article online at http://dx.doi.org/10.1016/j.ajhg.2014.04.006.

Acknowledgments
We thank the families and clinical staff at all locations for participation in this study. This work was supported in part by NIH grants to R.A.G. (NHGRI 5 U54 HG003273), J.R.L. (NHGRI RO1NS058529 and U54HG006542), and S.E.P. (NHGRI 5 U01 HG006485). M.W. received funding from the National Institute of Neurological Disorders and Stroke (NS076547) and the Simons Foundation. T.Y.T. is partially supported by the National Health and Medical Research Council of Australia (fellowship 607431). Baylor College of Medicine performs genetic testing as a service and Medical Research Council of Australia (fellowship 607431). Bainbridge, M.N., Hu, H., Muzny, D.M., Musante, L., Lupski, J.R., Graham, B.H., Chen, W., Gripp, K.W., Jenny, K., Wienker, T.F., et al. (2013). De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. Genome Med 5, 11.


